Clinical Trial Update: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line FOLFIRINOX for rectal cancer with synchronous non-resectable metastasis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Rectum
• Rectal Cancer

Drugs mentioned

• FOLFIRINOX

Snippet

Sponsor: Federation Francophone de Cancerologie Digestive | Conditions: Adenocarcinoma of Rectum | Phase 2 | Status: COMPLETED